Tag Archives: Andrew Fein

H.C. Wainwright Sticks to Their Buy Rating for Rubius Therapeutics (RUBY)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Rubius Therapeutics (RUBY – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $5.68. According to TipRanks.com, Fein is a 5-star analyst

Matinas BioPharma (MTNB) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $4.00. The company’s shares closed last Tuesday at $50.00. According to TipRanks.com, Fein is

H.C. Wainwright Keeps a Hold Rating on Syros Pharmaceuticals (SYRS)

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $11.00. The company’s shares closed last Friday at $12.20, close to its 52-week high of $12.75. According

Merus (MRUS) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Merus (MRUS – Research Report), with a price target of $23.00. The company’s shares closed last Thursday at $13.31. According to TipRanks.com, Fein is a

H.C. Wainwright Keeps a Buy Rating on BioCryst (BCRX)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BioCryst (BCRX – Research Report), with a price target of $13.00. The company’s shares closed last Thursday at $4.00. According to TipRanks.com, Fein is a

H.C. Wainwright Remains a Buy on Corbus Pharmaceuticals (CRBP)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $24.00. The company’s shares closed last Thursday at $6.33. According to TipRanks.com, Fein is a 4-star analyst